KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $205.2 million.

  • Castle Biosciences' Non-Current Assets rose 2086.31% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724.7 million, marking a year-over-year increase of 1027.98%. This contributed to the annual value of $171.1 million for FY2024, which is 848.17% up from last year.
  • Castle Biosciences' Non-Current Assets amounted to $205.2 million in Q3 2025, which was up 2086.31% from $196.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Non-Current Assets registered a high of $205.2 million during Q3 2025, and its lowest value of $10.7 million during Q1 2021.
  • Over the past 5 years, Castle Biosciences' median Non-Current Assets value was $156.3 million (recorded in 2023), while the average stood at $138.6 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 101802.96% in 2021, then plummeted by 639.22% in 2025.
  • Castle Biosciences' Non-Current Assets (Quarter) stood at $108.8 million in 2021, then surged by 42.46% to $155.0 million in 2022, then increased by 1.72% to $157.7 million in 2023, then grew by 8.48% to $171.1 million in 2024, then grew by 19.95% to $205.2 million in 2025.
  • Its Non-Current Assets stands at $205.2 million for Q3 2025, versus $196.1 million for Q2 2025 and $152.3 million for Q1 2025.